Immunoglobulin chimeric monomer-dimer hybrids

Patent metadata

Field	Value
Publication number	US-11401322-B2
Application number	US-201715465319-A
Country	US
Kind code	B2
Filing date	Mar 21, 2017
Priority date	May 6, 2003
Publication date	Aug 2, 2022
Grant date	Aug 2, 2022

Abstract

The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

First claim

The invention claimed is:

1. A method of treating a subject with a disease or condition, comprising administering a pharmaceutical composition to the subject, such that the disease or condition is treated, wherein the pharmaceutical composition comprises (a) a chimeric protein and (b) a pharmaceutically acceptable carrier, wherein the chimeric protein comprises a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises (i) a biologically active molecule selected from a hormone, a cytokine, or a cell surface receptor, and (ii) an immunoglobulin constant region or a portion thereof that is an FcRn binding partner; and wherein the second polypeptide chain consists of an immunoglobulin constant region or a portion thereof that is an FcRn binding partner, without any biologically active molecule or variable region of an immunoglobulin, wherein the immunoglobulin constant region or portion thereof in the first polypeptide chain and the immunoglobulin constant region or portion thereof in the second polypeptide chain are identical, and wherein the disease or condition can be treated by administration of the hormone, cytokine, or cell surface receptor.

2. The method of claim 1 , wherein each of the immunoglobulin constant regions or portions thereof is an Fc fragment.

3. The method of claim 1 , wherein the biologically active molecule comprises a hormone.

4. The method of claim 1 , wherein the biologically active molecule is human growth hormone (hGH), gonadotropin releasing hormone (GnRH), leuprolide, follicle stimulating hormone, progesterone, estrogen, or testosterone.

5. The method of claim 3 , wherein the hormone is hGH.

6. The method of claim 3 , wherein the hormone and the immunoglobulin constant region or the portion thereof in the first polypeptide chain are connected by a linker.

7. The method of claim 6 , wherein the linker comprises polyethylene glycol (PEG).

8. The method of claim 1 , wherein the biologically active molecule comprises a cytokine.

9. The method of claim 1 , wherein the biologically active molecule is granulocyte macrophage colony stimulating factor (GM-CSF), RANTES, MIP1α, MIP1β, IL-2, IL-3, Interferon α, Interferon β, tumor necrosis factor α, or tumor necrosis factor β.

10. The method of claim 9 , wherein the biologically active molecule is GM-CSF.

11. The method of claim 8 , wherein the cytokine and the immunoglobulin constant region or the portion thereof in the first polypeptide chain are connected by a linker.

12. The method of claim 11 , wherein the linker comprises polyethylene glycol (PEG).

13. The method of claim 1 , wherein the biologically active molecule comprises a cell surface receptor.

14. The method of claim 1 , wherein the biologically active molecule is CD4, CCR5, CXCR4, CD21, CD46, TNFα receptor, erythropoietin receptor, CD25, CD122, or CD132.

15. The method of claim 13 , wherein the cell surface receptor and the immunoglobulin constant region or the portion thereof in the first polypeptide chain are connected by a linker.

16. The method of claim 15 , wherein the linker comprises polyethylene glycol (PEG).

17. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject in combination with at least one other known agent to treat said disease or condition.

18. The method of claim 1 , wherein the pharmaceutical composition is formulated for intravenous, intramuscular, subcutaneous, oral, buccal, sublingual, nasal, parenteral, rectal, vaginal, mucosal, aerosol, or pulmonary delivery.

19. The method of claim 1 , wherein the pharmaceutical composition is administered intravenously, intramuscularly or subcutaneously to the subject.

20. The method of claim 1 , wherein the biologically active molecule is linked to the N-terminus of the portion of the immunoglobulin constant region or portion thereof of the first polypeptide chain.

21. The method of claim 6 , wherein the hormone is linked to the N-terminus of the portion of the immunoglobulin constant region or portion thereof of the first chain.

22. A method of treating a subject with a disease or condition, comprising administering a pharmaceutical composition to the subject, such that the disease or condition is treated, wherein the pharmaceutical composition comprises (a) a chimeric protein and (b) a pharmaceutically acceptable carrier, wherein the chimeric protein comprises a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises (i) a hormone, and (ii) an immunoglobulin constant region or a portion thereof that is an FcRn binding partner; and wherein the second polypeptide chain consists of an immunoglobulin constant region or a portion thereof that is an FcRn binding partner, without any biologically active molecule or variable region of an immunoglobulin.

23. The method of claim 22 , wherein the pharmaceutical composition is administered intravenously, intramuscularly or subcutaneously to the subject.

24. The method of claim 22 , wherein the hormone is linked to the N-terminus of the portion of the immunoglobulin constant region or portion thereof of the first chain.

25. The method of claim 22 , wherein the chimeric protein has a structure with the formula:
X-La-F:F or F:F-La-X,
wherein X is the hormone, L is an optional linker, F is an immunoglobulin constant region or a portion thereof that is an FcRn binding partner, and a is any integer or zero.

Assignees

• Bioverativ Therapeutics Inc

Inventors

• Peters Robert T
• Mezo Adam R
• Rivera Daniel S
• Bitonti Alan J
• Low Susan C

Classifications

• C07K14/475 Primary

  Growth factors; Growth regulators · CPC title

• A61K47/6835

  the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site · CPC title

• A61K47/642

  the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title